Clinical trial analysis is one of the main business directions and services in IQVIA, and reviewing past similar studies is one of the most critical steps before starting a commercial clinical trial. The current review process is manual and time-consuming, requiring a clinical trial analyst to manually search through an extensive clinical trial database and then review all candidate studies. Therefore, it is of great interest to develop an automatic retrieval algorithm to select similar studies by giving new study information. To achieve this goal, we propose a novel group-based trial similarity learning network named GTSLNet, consisting of two kinds of similarity learning modules. The pair-wise section-level similarity learning module aims to compare the query trial and the candidate trial from the abstract semantic level via the proposed section transformer. Meanwhile, a word-level similarity learning module uses the word similarly matrix to capture the low-level similarity information. Additionally, an aggregation module combines these similarities. To address potential false negatives and noisy data, we introduce a variance-regularized group distance loss function. Experiment results show that the proposed GTSLNet significantly and consistently outperforms state-of-the-art baselines.

Clinical trials aim to study new tests and evaluate their effects on human health outcomes, which has a huge market size. However, carrying out clinical trials is expensive and time-consuming and often ends in no results. It will revolutionize clinical practice if we can develop an effective model to automatically estimate the status of a clinical trial and find out possible failure reasons. However, it is challenging to develop such a model because of the lack of a benchmark dataset. To address these challenges, in this paper, we first build a new dataset by extracting the publicly available clinical trial reports from ClinicalTrials.gov. The associated status of each report is treated as the status label. To analyze the failure reasons, domain experts help us manually annotate each failed report based on the description associated with it. More importantly, we examine several state-of-the-art text classification baselines on this task and find out that the unique format of the clinical trial protocols plays an essential role in affecting prediction accuracy, demonstrating the need for specially designed clinical trial classification models.

Predicting adverse drug reactions (ADRs) of drugs is one of the most critical steps in drug development. By pre-estimating the adverse reactions, researchers and drug development companies can greatly prevent the potential ADR risks and tragedies. However, the current ADR prediction methods suffer from several limitations. First, the prediction results are based on pure drug-related information, which makes them impossible to be directly applied for the personalized ADR prediction task. The lack of personalization of models also makes rare adverse events hard to be predicted. Therefore, it is of great interest to develop a new personalized ADR prediction method by introducing additional sources, e.g., patient health records. However, few methods have tried to use additional sources. In the meantime, the variety of different source formats and structures makes this task more challenging. To address the above challenges, we propose a novel personalized multi-sourced-based drug adverse reaction prediction model named pADR. pADR first works on every single source to transform them into proper representations. Next, a hierarchical multi-sourced Transformer is designed to automatically model the interactions between different sources and fuse them together for the final adverse event prediction. Experimental results on a new multi-sourced ADR prediction dataset show that PADR outperforms state-of-the-art drug-based baselines. Moreover, the case and ablation studies also illustrate the effectiveness of our proposed fusion strategies and the reasonableness of each module design.

Population-level disease prediction estimates the number of potential patients of particular diseases in some location at a future time based on (frequently updated) historical disease statistics. Existing approaches often assume the existing disease statistics are reliable and will not change. However, in practice, data collection is often time-consuming and has time delays, with both historical and current disease statistics being updated continuously. In this work, we propose a real-time population-level disease prediction model which captures data latency (PopNet) and incorporates the updated data for improved predictions. To achieve this goal, PopNet models real-time data and updated data using two separate systems, each capturing spatial and temporal effects using hybrid graph attention networks and recurrent neural networks. PopNet then fuses the two systems using both spatial and temporal latency-aware attentions in an end-to-end manner. We evaluate PopNet on real-world disease datasets and show that PopNet consistently outperforms all baseline disease prediction and general spatial-temporal prediction models, achieving up to 47% lower root mean squared error and 24% lower mean absolute error compared with the best baselines.

The goal of molecular optimization is to generate molecules similar to a target molecule but with better chemical properties. Deep generative models have shown great success in molecule optimization. However, due to the iterative local generation process of deep generative models, the resulting molecules can significantly deviate from the input in molecular similarity and size, leading to poor chemical properties. The key issue here is that the existing deep generative models restrict their attention on substructure-level generation without considering the entire molecule as a whole. To address this challenge, we propose Molecule-Level Reward functions (MOLER) to encourage (1) the input and the generated molecule to be similar, and to ensure (2) the generated molecule has a similar size to the input. The proposed method can be combined with various deep generative models. Policy gradient technique is introduced to optimize reward-based objectives with small computational overhead. Empirical studies show that MOLER achieves up to 20.2% relative improvement in success rate over the best baseline method on several properties, including QED, DRD2 and LogP.

Drug discovery aims at finding promising drug molecules for treating target diseases. Existing computational drug discovery methods mainly depend on molecule databases, ignoring valuable data collected from clinical trials. In this work, we propose PRIME to leverage high-quality drug molecules and drug-disease relations in historical clinical trials to narrow down the molecular search space in drug discovery. PRIME also introduces time dependency constraints to model evolving drug-disease relations using a probabilistic deep learning model that can quantify model uncertainty. We evaluated PRIME against leading models on both de novo design and drug repurposing tasks. Results show that compared with the best baselines, PRIME achieves 25.9% relative improvement (i.e., reduction) in average hit-ranking on drug repurposing and 47.6% relative improvement in success rate on de novo design.

Successful health risk prediction demands accuracy and reliability of the model. Existing predictive models mainly depend on mining electronic health records (EHR) with advanced deep learning techniques to improve model accuracy. However, they all ignore the importance of publicly available online health data, especially socioeconomic status, environmental factors, and detailed demographic information for each location, which are all strong predictive signals and can definitely augment precision medicine. To achieve model reliability, the model needs to provide accurate prediction and uncertainty score of the prediction. However, existing uncertainty estimation approaches often failed in handling high-dimensional data, which are present in multi-sourced data.

Clinical trials play important roles in drug development but often suffer from expensive, inaccurate and insufficient patient recruitment. The availability of massive electronic health records (EHR) data and trial eligibility criteria (EC) bring a new opportunity to data driven patient recruitment. One key task named patient-trial matching is to find qualified patients for clinical trials given structured EHR and unstructured EC text (both inclusion and exclusion criteria). How to match complex EC text with longitudinal patient EHRs? How to embed many-to-many relationships between patients and trials? How to explicitly handle the difference between inclusion and exclusion criteria? In this paper, we proposed CrOss-Modal PseudO-SiamEse network (COMPOSE) to address these challenges for patient-trial matching. One path of the network encodes EC using convolutional highway network. The other path processes EHR with multi-granularity memory network that encodes structured patient records into multiple levels based on medical ontology. Using the EC embedding as query, COMPOSE performs attentional record alignment and thus enables dynamic patient-trial matching. COMPOSE also introduces a composite loss term to maximize the similarity between patient records and inclusion criteria while minimize the similarity to the exclusion criteria. Experiment results show COMPOSE can reach 98.0% AUC on patient-criteria matching and 83.7% accuracy on patient-trial matching, which leads 24.3% improvement over the best baseline on real-world patient-trial matching tasks.

Generating clinical reports from raw recordings such as X-rays and electroencephalogram (EEG) is an essential and routine task for doctors. However, it is often time-consuming to write accurate and detailed reports. Most existing methods try to generate the whole reports from the raw input with limited success because 1) generated reports often contain errors that need manual review and correction, 2) it does not save time when doctors want to write additional information into the report, and 3) the generated reports are not customized based on individual doctors’ preference. We propose CLinicAl Report Auto-completion (, an interactive method that generates reports in a sentence by sentence fashion based on doctors’ anchor words and partially completed sentences. earches for most relevant sentences from existing reports as the template for the current report. The retrieved sentences are sequentially modified by combining with the input feature representations to create the final report. In our experimental evaluation chieved 0.393 CIDEr and 0.248 BLEU-4 on X-ray reports and 0.482 CIDEr and 0.491 BLEU-4 for EEG reports for sentence-level generation, which is up to 35% improvement over the best baseline. Also via our qualitative evaluation, s shown to produce reports which have a significantly higher level of approval by doctors in a user study (3.74 out of 5 for s 2.52 out of 5 for the baseline).

Deep learning has demonstrated success in health risk prediction especially for patients with chronic and progressing conditions. Most existing works focus on learning disease patterns from longitudinal patient data, but pay little attention to the disease progression stage itself. To fill the gap, we propose a Stage-aware neural Network (StageNet) model to extract disease stage information from patient data and integrate it into risk prediction. StageNet is enabled by (1) a stage-aware long short-term memory (LSTM) module that extracts health stage variations unsupervisedly; (2) a stage-adaptive convolutional module that incorporates stage-related progression patterns into risk prediction. We evaluate StageNet on two real-world datasets and show that StageNet outperforms state-of-the-art models in risk prediction task and patient subtyping task. Compared to the best baseline model, StageNet achieves up to 12% higher AUPRC for risk prediction task on two real-world patient datasets. StageNet also achieves over 58% higher Calinski-Harabasz score (a cluster quality metric) for a patient subtyping task.

Clinical trials are essential for drug development but often suffer from expensive, inaccurate and insufficient patient recruitment. The core problem of patient-trial matching is to find qualified patients for a trial, where patient information is stored in electronic health records (EHR) while trial eligibility criteria (EC) are described in text documents available on the web. How to represent longitudinal patient EHR? How to extract complex logical rules from EC? Most existing works rely on manual rule-based extraction, which is time consuming and inflexible for complex inference. To address these challenges, we proposed a cross-modal inference learning model to jointly encode enrollment criteria (text) and patients records (tabular data) into a shared latent space for matching inference. pplies a pre-trained Bidirectional Encoder Representations from Transformers(BERT) model to encode clinical trial information into sentence embedding. And uses a hierarchical embedding model to represent patient longitudinal EHR. In addition, s augmented by a numerical information embedding and entailment module to reason over numerical information in both EC and EHR. These encoders are trained jointly to optimize patient-trial matching score. We evaluated n the trial-patient matching task with demonstrated on real world datasets. utperformed the best baseline by up to 12.4% in average F1.